Efficacy of gemcitabine in patients with non-resectable pancreatic cancer by Popiela, Tadeusz et al.
NOWOTWORY 2001 / tom 51
Zeszyt 2 / 117-121
Efficacy of gemcitabine in patients with non-resectable pancreatic cancer: 
prospective clinical studies
Tadeusz Popiela, Bogusław Kędra, Marek Sierżęga
A  i m. Cancer o f the pancreas continues to be a leading cause o f cancer deaths. The aim o f our study was to assess the effect 
o f gemcitabine-based chemotherapy regimen on treatment outcomes in patients with non-resectable pancreatic cancer. 
M a t e r i a l  a n d  me t h o d s .  Sixty-one patients were qualified on the basis o f intraoperative tumour staging. On day 10 fo l­
lowing surgery patients were randomised to form a treatment group receiving 1000 mg/m2 gemcitabine (group I) and a con­
trol group (group II).
R e s u l t s .  No statistically significant differences were seen between the groups regarding clinical and pathological characte­
ristics. A  positive response to chemotherapy was noted in 11 (35.5%) o f the patients so treated. A n  objective positive respon­
se (reduction in tumour size or no change) was confirmed in follow-up diagnostic imaging examinations in 7patients in gro­
up I  and 1 patient in group I I  (p<0.05). The percentage o f patients whose tumours increased in size by less than 10% from ba­
seline was considerably higher in the treatment group (62.9%) than in the control group (33.3%), at p<0.01. Group 
I  patients also required less use o f analgesics, more often experienced no weight loss and were clinically better o ff than the con­
trols in group II  (p<0.01). Mean survival time o f gemcitabine-treated patients was 6.7 months, which was significantly lon­
ger than in the control group (4.5 months, p<0.01). Side effects, mostly transient leukopenia, were observed in 22% o f patients 
during the study.
C o n c l u s i o n .  On the basis o f these results, the authors recommend gemcitabine-based chemotherapy regimens as the tre­
atment o f choice in non-resectable pancreatic carcinoma.
Ocena skuteczności gemcytabiny w leczeniu chorych z nieresekcyjnym rakiem trzustki: 
prospektywne badania kliniczne
Rak trzustki pozostaje nadal jedną z  wiodących przyczyn zgonów na nowotwory złośliwe. Celem niniejszej pracy była ocena 
wpływu chemioterapii, opartej na gemcytabinie, na wyniki leczenia chorych z  nieresekcyjnym rakiem trzustki. W  oparciu 
o śródoperacyjną ocenę stopnia zaawansowania nowotworu do badania włączono 61 chorych. W 10 dobie po zabiegu ope­
racyjnym chorych randomizowano do grupy terapeutycznej, otrzymującej gemcytabinę w ilości 1000 mg/m2 (grupa I) lub gru­
py kontrolnej (grupa II). Nie stwierdzono istotnych statystycznie różnic, dotyczących cech kliniczno-patologicznych między ba­
danymi grupami. U 11 (35.5%) chorych, otrzymujących chemioterapię, stwierdzono cechy odpowiedzi pozytywnej. Obiektyw­
ną odpowiedź pozytywną w postaci częściowej regresji lub stabilizacji wymiarów guza stwierdzono w kontrolnych badaniach 
obrazowych u 7 chorych w grupie I i  1 chorego w grupie II  (p<0.05). Odsetek chorych, u których stwierdzono progresję ma­
sy guza poniżej 10% stanu wyjściowego, w grupie otrzymującej chemioterapię był znacznie wyższy (62.9%), w porównaniu do 
grupy kontrolnej (33.3%); p<0.01. Chorzy w grupie I  wymagali stosowania mniejszej ilości środków przeciwbólowych, czę­
ściej utrzymywali stałą wagę ciała oraz byli w lepszym stanie klinicznym w porównaniu do grupy I I  (p<0.01). Średni czas prze­
życia chorych otrzymujących gemcytabinę wynosił 6.7 miesiąca i w porównaniu z  grupą kontrolną (4.5 miesiąca) był znaczą­
co dłuższy (p<0.01). W  czasie badania objawy uboczne chemioterapii obserwowano u 22% chorych i dotyczyły one głównie 
przejściowej leukopenii. Na podstawie uzyskanych wyników autorzy rekomendują stosowanie chemioterapii, opartej na 
gemcytabinie, jako leczenie z  wyboru w przypadku nieresekcyjnych raków trzustki.
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Introduction
Cancer of the pancreas accounts for 5-8% of all cancers 
and is the fifth most frequent cause of cancer-related de­
aths in Western European countries and the USA [1-3]. 
Since 1960, the pancreatic cancer mortality rate in Poland 
has been growing to reach 13.1 per 100.000 in 1996 [4]. 
This form of cancer is usually diagnosed at an advanced 
stage so that only 20-30% of patients are qualified for re­
section surgery while others can only benefit from palliati­
ve treatment that ameliorates the clinical symptoms [3, 
5-7]. Palliative treatment will usually make possible a tem­
porary remission of a few months' duration in about 30% 
of patients. Mean survival time of patients with an advan­
ced pancreatic carcinoma is 3-6 months, with 90% not 
surviving beyond one year since diagnosis. Chemotherapy 
regimens used to date for patients with advanced pancre­
atic cancer, based on 5-fluorouracil, adriamycin, streptozo- 
cin or mitomycin C, have produced a positive clinical re­
sponse only in 4-5% of patients [8-10]. At the same time, 
literature on gemcitabine published in recent years sugge­
sts better treatment outcomes in advanced pancreatic can­
cer with gemzar-based chemotherapy [11-14].
The aim of this study was to evaluate the effect of 
gemcitabine on clinical outcomes in patients with non- 
-resectable cancer of the pancreas.
Patients and methods
The participants of the study were patients with a confirmed 
diagnosis of pancreatic cancer who underwent surgery at the 
1st Chair of General Surgery CM UJ between September 1996 
and D ecember 1998. In all patients the diagnosis and local sta­
ging data were verified intraoperatively during a laparotomy 
procedure. The following criteria were used in qualifying pa­
tients for treatment:
1. Histopathologically confirmed adenocarcinoma of the pan­
creas
2. Intraoperatively confirmed non-resectable tumour (stage 
IV according to TNM/UICC)
3. Patient age: 18-70 years
4. Clinical status >50 pts (Karnofsky scale)
5. Plasma bilirubin <32 mmol/l
6. AspAT, AlAT <80 U/l
7. Plasma albumin >28 g/l
8. Leukocyte count >4000, platelet count >100,000/mm3
9. Absence of signs of cardiovascular or respiratory insuffi­
ciency
10. Informed consent to participate obtained from the patient
Patients who met all the above criteria were randomised in­
to two clinical groups: Group I, which received gemcitabine- 
-based palliative chemotherapy, and Group II, receiving only 
symptomatic treatment.
Palliative chemotherapy was based on the following regi­
men: starting from the tenth day following surgery, 1000 mg/m2 
gemcitabine was given in a continuous intravenous infusion over 
30 minutes, once a week over 7 weeks. After a week's break, 
treatm ent was continued for another 3 weeks. Treatment outco­
mes were evaluated in both groups at 12 weeks after surgery. If 
a positive response was observed, treatm ent was continued until 
the disease was in progress, toxic side effects occurred or the pa­
tient withdrew consent to further treatment.
Examinations carried out in both groups every week inclu­
ded body weight measurements and toxicity assessment based on 
the ECO G  scale. Additionally, the tum our mass was monito­
red using imaging diagnostics (CT, USG): tumour size was me­
asured before the surgery and at 12 weeks after the surgery. 
Quality of life was also assessed using general status data (based 
on the Karnofsky scale) and the amount and type of analgesic 
medications required. A  positive clinical response was defined as 
an improvement of one of the param eters continuing over 4 
weeks without deterioration in any other param eter, and in the 
setting of increasing tum our size. An objective positive respon­
se was defined as stabilisation or reduction of tum our size seen 
in the follow-up imaging exam.
The results were analysed using the Statistica 5.5 software 
package (StatSoft). Variables were tested using the chi-squared 
test, long-term survival in the study groups was evaluated by 
the Kaplan-M eier method and compared using the log-rank 
test. The value of p=0.05 was regarded as statistically significant.
Results
Sixty-one patients treated for pancreatic cancer betwe­
en September 1996 and December 1998 were qualified 
for the study (32 men, 29 women). Demographic charac­
teristics are presented in Table I. Following intraoperati­
ve clinical staging of the tumour, the patients were rando­
mised into two clinical groups.
Tab. I. Demographic data breakdown per study group
Gemcitabine
n=31
Controls
n=30 P
Gender
F 14 15 NS
M 17 15
Tumour location
H ead 19 18 NS
Body 9 10
Tail 3 2
TNM  classification stage
IVA 12 14 NS
IVB 19 16
Type of surgical procedure
Choledochoduodenostomy + gastroenterostomy 19 18
G astroenterostomy 3 1 NS
Laparotomy 9 11
Group I (gemcitabine group) consisted of 31 pa­
tients (14 women and 17 men) aged 59.9±12.3 years. 19 
patients had carcinoma of the pancreatic head, 9 had 
a lesion in the body and the remaining three, in the tail of 
the pancreas. 12 patients had a stage IVA tumour and 
the remaining 19 had a stage IVB tumour, according to 
the TNM/UICC classification (1997) [15]. Bypass ana­
stomoses (choledochoduodenostomies and gastroente­
rostomies) were formed in the 19 patients with carcinoma 
of the head, 3 patients had only gastrostomy performed 
and in the remaining 9 the surgical intervention was limi­
ted to an exploratory laparotomy.
The second group (control group) consisted of 30 
patients (15 women and 15 men) aged 60.2±11.3 years. 
Location of the tumour was similar to that observed in 
group I, with involvement of the pancreatic head in 18 pa­
tients, body in 10 and tail in the remaining 2. Fourteen pa­
tients had a stage IVA tumour, and the remaining 16, an 
IVB tumour. The number and type of surgical procedures 
performed were similar to those carried out in group 
I patients. There were no statistically significant diffe­
rences between the groups regarding demographics, tu­
mour stage and type of surgical intervention (Tab. I).
Following a course of 10 cycles of gemcitabine treat­
ment, a positive response was observed in 11 (35.5%) pa­
tients. An objective positive response was noted in 7 pa­
tients and the remaining 4 showed only clinically positive 
response, that is improvement in overall clinical status, di­
sappearance of pain and stabilisation of body weight. The 
remaining 20 patients (64.5%) showed no signs of a posi­
tive response (Tab. II).
Tab. II. Response to chemotherapy (n=31)
Positive 
n = 
objective 
n= 6
response
11
clinical
n= 4
No 
response 
n = 21
P
Gender
F 3 2 10 NS
M 4 2 11
Mean age (years) 59.2 62.1 58.2 NS
Tumour location
Head 2 2 15 NS
Body or tail 5 2 6
TNM /UICC stage
IVA 4 2 7
IVB 3 2 14 NS
There were no differences in age or gender between 
those patients on chemotherapy who responded and those 
who did not. A relatively higher percentage of responders 
was seen with carcinomas of the body and tail (7/13) com­
pared to carcinomas of the pancreatic head (4/19). Howe­
ver, this finding was not statistically significant. No relation­
ship was also established between the TNM/UICC tumour
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Fig. 1. Long-term survival in the study groups
stage and a positive response, which was observed sym­
metrically in patients with IVA and IVB stage tumours.
In 92% (57/61) of the patients, tumour size was objec­
tively determined at the follow-up examination. In the re­
maining patients, adequate tumour images could not be 
obtained due to technical difficulties so that a reliable as­
sessment was impossible. Table III shows the results of 
the measurement. In group I, reduction or stabilisation 
of the size of the tumour mass was observed in 25.9% (7) 
of the patients, compared to 3.3% (1) in the control group 
and these between-group differences were statistically si­
gnificant (p<0.05). Reduction of tumour size was seen in 
2 patients in group I, which made it possible to perform 
palliative resection of the body and tail of the pancreas fol­
lowing 6-month chemotherapy in one of them. Increase in 
tumour size was seen in the majority of the patients in 
both groups: 74% (20) of patients in the gemcitabine gro­
up and 96.7% (29) of patients in the control group, but the 
„profile” of disease progression was different. In group 
I, an increase in tumour size of more than 10% from base­
line was seen in 11.1% (3) of patients, compared to as 
many as 63.4% (19) of patients in group II. More patients 
in group I (62.9%) had an increase in tumour size of less 
than 10% above baseline than in group II (33.3%). These 
differences were also statistically significant (p<0.01).
Tab. III. Change in tumour size (ultrasound, CT)
Size of tum our mass Gemcitabine
n=27
Controls
n=30 P
Reduction 2 (7.4%) 0 (0%) <0.05
Stabilisation 5 (18.6%) 1 (3.3%)
Increase 20 (74.0%) 29 (96.7%)
< 10% 17 (62.9%) 10 (33.3%) <0.01
> 10% 3 (11.1%) 19 (63.4%)
The changes in the size of tumour mass correlated 
with the clinical picture in both groups, as shown in Table 
IV. Overall clinical status, assessed using the Karnofsky 
scale, was considerably better in the patients receiving 
Gemzar. More than 51% (16) of the patients in this gro­
up scored above 70 points, compared to 17% (5) in the 
control group. Also, in the control group more than 83% 
(25) scored below 70 points (p<0.01). Weight loss was 
also markedly faster among patients in the control group 
(93% vs 64%) compared to the gemcitabine-treated pa­
120
tients (p<0.01). Patients in the control group also re­
quired more analgesics than those in group I (p<0.01) 
and the proportion of narcotic drugs among analgesics 
was higher in the control group, too. Mean survival time 
in group I was 6.7 months and was longer by more than 2 
months than in group II (4.5 months, p<0.01). Mean su­
rvival time was 11.1 months in patients with a positive 
response. The longest survival time was seen in the pa­
tient in whom, following 6-month chemotherapy, palliati­
ve resection surgery was performed.
Tab. IV Quality of life comparison
Gemcitabine
n=31
Controls
n=30
P
Use of analgesic medications 12 23 <0.01
non-narcotic 9 13
narcotic 3 10
G eneral status (Karnofsky scale) 
<70 pts 15 25
<0.01
>70 pts 16 5
Body weight 
stable 11 2
<0.01
lower 17 18
cachexia 3 10
M ean survival time
(months) 6.7 4.5 <0.01
(11.1)*
* Responding patients
The assessment of toxicity of the gemcitabine treat­
ment revealed only minor side effects (Table V), with 
transient leukopenia in 22.5% of the patients, thrombocy­
topenia in 19.3%, anaemia in 12.9%, nausea and vomiting 
and transient peripheral oedema in 19.3% of the gemcita- 
bine-treated patients.
Tab. V. Chemotherapy toxicity assessment (WHO criteria)
Parameter I° II° III° VI° %
Leukopenia 4 2 1 - 22.5
Thrombocytopenia 2 3 1 - 19.3
Anaemia 2 1 1 - 12.9
Nausea/vomiting 3 2 1 - 19.3
D iarrhoea 1 1 - - 6.4
Oedem a 2 3 1 - 19.3
Discussion
Gemcitabine (gemcitabine hydrochloride) is a new cytosta­
tic of the antimetabolite group. It is a deoxycytidine analo­
gue which exhibits cytostatic activity following transforma­
tion to active metabolites. Deoxycytidine kinase mediates 
the phosphorylation of gemcitabine to bi- and triphospha­
tes. These block DNA synthesis and error correction thro­
ugh inhibitory action on DNA polymerase and ribo­
nucleotide reductase. Clinical studies carried out to date 
have demonstrated that gemcitabine is effective in patients 
with non-small cell carcinoma of the lung and other solid 
tumours, mainly carcinomas of the breast and ovary [8, 
16]. Since the mid-1990's it has also been approved in the 
USA for palliative treatment of pancreatic carcinoma.
Prospective randomised clinical studies of gemcitabi- 
ne in a homogeneous group of patients with inoperable 
pancreatic cancer minimise the possibility of an error in 
evaluating the efficacy of gemcitabine. Preoperative 
staging of pancreatic cancer is not fully reliable despite 
the use of modern diagnostic procedures [18, 19]. It was 
for this reason that only patients in whom intraoperative 
staging was carried out were qualified for the study.
Our results confirm earlier reports by other authors 
that gemcitabine is highly effective in the treatment of 
pancreatic cancer [11-14]. A positive response noted in 
more than 30% of all patients receiving Gemzar represen­
ted a much higher percentage than has been observed 
with other chemotherapy regimens [8-10].
Partial regression of the tumour in 2 of the patients 
(7.4%), confirmed by follow-up imaging examinations, 
made it possible to carry out a palliative resection proce­
dure in one of them later on. Even though the percentage 
of patients with tumour size reduction was small, it indica­
tes potential benefits of using Gemzar as a neoadjuvant in 
the treatment of locally advanced pancreatic carcinoma. 
Despite signs of progression of disease in 74% of the pa­
tients receiving chemotherapy, the increase in tumour si­
ze was usually much less marked than in the control gro­
up. A slowing down of the rate of disease progression, 
seen in most of the patients receiving Gemzar, led to 
a considerable improvement in their overall clinical status. 
Stabilisation of body weight and reduction of the amount 
of analgesics required, together with the improvement 
in general status, are indicative of high palliative efficacy 
of the chemotherapy regimen under study. Thus, even in 
the setting of progressing cancer, patients can be offe­
red effective palliative management.
Prolongation of patient survival time is the most ob­
jective criterion of treatment efficacy. Our analysis showed 
a significant lengthening of mean survival time in the gem- 
citabine group compared to the control group (6.7 vs 4.5 
months), which concurs with the findings of other authors 
[8, 10-14]. Mean survival time was even longer (11.1 mon­
ths) among the 11 (32%) responding patients.
Untoward side effects associated with gemcitabine 
are not different from those produced by other cytostatics 
medications. Minor bone marrow suppression seen in 
22.5% of the patients indicates that the chemotherapy 
treatment under study is considerably safe.
Conclusions
On the basis of their results, the authors recommend 
gemcitabine-based chemotherapy as the treatment of 
choice for patients with non-resectable pancreatic can­
cer. The high efficacy of the Gemzar treatment in the 
group of patients in this study prompted the authors to
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undertake another clinical study where gemcitabine is 
used as supplementary treatment following resection of 
pancreatic carcinoma in monotherapy or combination 
therapy with leucovorin and cisplatin.
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